# Zepp Health Corp: Form 20-F for the period ended Dec 31, 2021

- Company: [Zepp Health Corp](/companies/zepp.md) (CIK 1720446)
- Form: 20-F
- Filed: 2022-04-28
- Accepted by EDGAR: Apr 28, 2022, 16:55 ET
- Period: 2021-12-31
- Accession: 0001104659-22-052369
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1720446/000110465922052369/zepp-20211231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1720446/000110465922052369/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-01-01 to 2021-12-31 | $980.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months, 2021-01-01 to 2021-12-31 | $775.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months, 2021-01-01 to 2021-12-31 | $204.9m | us-gaap:GrossProfit |
| Research and development | 12 months, 2021-01-01 to 2021-12-31 | $80.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | $14.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2021-01-01 to 2021-12-31 | $7.0m | us-gaap:InterestExpense |
| Income tax | 12 months, 2021-01-01 to 2021-12-31 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | $21.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2021-01-01 to 2021-12-31 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2021-01-01 to 2021-12-31 | $0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2021-01-01 to 2021-12-31 | 264,368,629 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | −$36.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | $7.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months, 2021-01-01 to 2021-12-31 | $2.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-12-31 | $230.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-12-31 | $616.9m | us-gaap:AssetsCurrent |
| Total assets | at 2021-12-31 | $955.0m | us-gaap:Assets |
| Current liabilities | at 2021-12-31 | $337.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-12-31 | $494.6m | us-gaap:Liabilities |
| Long-term debt | at 2021-12-31 | $114.1m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2021-12-31 | $458.3m | us-gaap:StockholdersEquity |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1720446/000110465922052369/zepp-20211231x20f.htm

Filed Apr 28, 2022.
Source: SEC EDGAR, the filing index for accession 0001104659-22-052369. Last ingested by Listed: Nov 5, 2026, 14:06 ET. No prices; not investment advice.